The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...

AstraZeneca is already the largest pharmaceutical company in China and the country accounts for 12pc of its revenues. However ...

British pharmaceutical giant AstraZeneca on Friday announced plans to invest $2.5 billion in China, despite the detention ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was detained by authorities.

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to ...